Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes

Rosalie A. Scholtes; Anne C. Hesp; Charlotte M. Mosterd; Frank Geurts; Ewout J. Hoorn; Daan J. Touw; Merle M. Krebber; Jaap A. Joles; Hiddo J. L. Heerspink; Daniël H. van Raalte

doi:https://doi.org/10.1161/CIRCULATIONAHA.122.061033

Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes

Rosalie A. Scholtes, Anne C. Hesp, Charlotte M. Mosterd, Frank Geurts, Ewout J. Hoorn, Daan J. Touw, Merle M. Krebber, Jaap A. Joles, Hiddo J. L. Heerspink, Daniël H. van Raalte

Research output: Contribution to journal › Comment/Letter to the editor › Academic

3 Citations (Scopus)

Original language	English
Pages (from-to)	1895-1897
Number of pages	3
Journal	Circulation
Volume	146
Issue number	24
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.122.061033
Publication status	Published - 13 Dec 2022

Keywords

angiotensin receptor blocker
diabetic kidney disease
sodium glucose cotransporter-2 inhibitor
type 2 diabetes mellitus

Access to Document

https://doi.org/10.1161/CIRCULATIONAHA.122.061033

Cite this

Scholtes, R. A., Hesp, A. C., Mosterd, C. M., Geurts, F., Hoorn, E. J., Touw, D. J., Krebber, M. M., Joles, J. A., Heerspink, H. J. L., & van Raalte, D. H. (2022). Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes. Circulation, 146(24), 1895-1897. https://doi.org/10.1161/CIRCULATIONAHA.122.061033

@article{67240acc91d74f289231917ce358d0cc,

title = "Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes",

keywords = "angiotensin receptor blocker, diabetic kidney disease, sodium glucose cotransporter-2 inhibitor, type 2 diabetes mellitus",

author = "Scholtes, {Rosalie A.} and Hesp, {Anne C.} and Mosterd, {Charlotte M.} and Frank Geurts and Hoorn, {Ewout J.} and Touw, {Daan J.} and Krebber, {Merle M.} and Joles, {Jaap A.} and Heerspink, {Hiddo J. L.} and {van Raalte}, {Dani{\"e}l H.}",

note = "Funding Information: R.A.S., A.C.H., C.M.M., F.G., E.J.H., M.M.K., and J.A.J. report no conflicts. D.H.vR. has acted as a consultant for and received honoraria from Boehringer Ingelheim-Eli Lilly Alliance, Merck, Sanofi, and AstraZeneca, and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Merck. All honoraria are paid to his employer (Amsterdam University Medical Centers, location VUMC). D.J.T. reports grants from ZONMW and Chiesi Pharmaceuticals, as well as fees to his institution from ZONMW and PurelMS. H.J.L.H. has received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen, as well as fees to his institution for his participation on advisory boards from Merck, Mitsubishi Tanabe, Janssen, and Mundipharma; for consulting from AbbVie, Retrophin, Boehringer Ingelheim, and Novo Nordisk; and for participation in steering committees from Janssen, Gilead, Bayer, Chinook, and CSL Pharma.",

year = "2022",

month = dec,

day = "13",

doi = "https://doi.org/10.1161/CIRCULATIONAHA.122.061033",

language = "English",

volume = "146",

pages = "1895--1897",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "24",

}

Scholtes, RA , Hesp, AC , Mosterd, CM, Geurts, F, Hoorn, EJ, Touw, DJ, Krebber, MM, Joles, JA, Heerspink, HJL & van Raalte, DH 2022, 'Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes', Circulation, vol. 146, no. 24, pp. 1895-1897. https://doi.org/10.1161/CIRCULATIONAHA.122.061033

Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes. / Scholtes, Rosalie A.; Hesp, Anne C.; Mosterd, Charlotte M. et al.
In: Circulation, Vol. 146, No. 24, 13.12.2022, p. 1895-1897.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination

T2 - A Crossover Randomized Trial in People with Type 2 Diabetes

AU - Scholtes, Rosalie A.

AU - Hesp, Anne C.

AU - Mosterd, Charlotte M.

AU - Geurts, Frank

AU - Hoorn, Ewout J.

AU - Touw, Daan J.

AU - Krebber, Merle M.

AU - Joles, Jaap A.

AU - Heerspink, Hiddo J. L.

AU - van Raalte, Daniël H.

N1 - Funding Information: R.A.S., A.C.H., C.M.M., F.G., E.J.H., M.M.K., and J.A.J. report no conflicts. D.H.vR. has acted as a consultant for and received honoraria from Boehringer Ingelheim-Eli Lilly Alliance, Merck, Sanofi, and AstraZeneca, and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Merck. All honoraria are paid to his employer (Amsterdam University Medical Centers, location VUMC). D.J.T. reports grants from ZONMW and Chiesi Pharmaceuticals, as well as fees to his institution from ZONMW and PurelMS. H.J.L.H. has received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen, as well as fees to his institution for his participation on advisory boards from Merck, Mitsubishi Tanabe, Janssen, and Mundipharma; for consulting from AbbVie, Retrophin, Boehringer Ingelheim, and Novo Nordisk; and for participation in steering committees from Janssen, Gilead, Bayer, Chinook, and CSL Pharma.

PY - 2022/12/13

Y1 - 2022/12/13

KW - angiotensin receptor blocker

KW - diabetic kidney disease

KW - sodium glucose cotransporter-2 inhibitor

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85143994669&partnerID=8YFLogxK

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85143994669&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/36508495

U2 - https://doi.org/10.1161/CIRCULATIONAHA.122.061033

DO - https://doi.org/10.1161/CIRCULATIONAHA.122.061033

M3 - Comment/Letter to the editor

C2 - 36508495

SN - 0009-7322

VL - 146

SP - 1895

EP - 1897

JO - Circulation

JF - Circulation

IS - 24

ER -

Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes

Keywords

Access to Document

Other files and links

Cite this